Biotech News
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 Enrollment ongoing in the Phase II COVALENT-212 clinical trial evaluating icovamenib in patients with
